BioSpace News Archive

In a press release Friday, Genentech announced approval of Vabysmo™ (faricimab-svoa), a new advancement in the treatment approach for Wet Age-Related Macular Degeneration (AMD) and diabetic macular edema (DME).

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the National Health Service (NHS) that enables access to Libmeldy® (atidarsagene autotemcel) for all children with metachromatic leukodystrophy (MLD) in England and Wales who fall within the scope of the European marketing authorization.

Seagen Inc. (Nasdaq:SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival.

Ermium Therapeutics is announcing today the establishment of a scientific advisory board.

Xavo, a leading provider of Software-as-a-Service for Biopharma R&D with offices in Boston, MA , Bayreuth, Germany and Basel, Switzerland , announced today the release of the latest version of its Lab Operations Management Platform, which is called Xavo R3.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer.

We are excited to announce that our new toxicology facility in Suzhou, China has achieved a key milestone when Jiangsu’s Provincial Department of Science and Technology granted the site an “Experimental Animal Use License” on January 21, 2022, following an on-site inspection and review of recently completed construction.

According to Emergen Research, the global electrosurgical devices market size was USD 4.80 billion in 2019 and is expected to reach USD 7.62 billion in 2027 and register a revenue CAGR of 6.3% during the forecast period.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022.

According to Emergen Research, the global depression treatment market size was USD 12.06 billion in 2019 and is expected to reach USD 16.06 billion in 2027 and register a revenue CAGR of 3.9% during the forecast period, 2020-2027.